Justin Ho


Dr. Justin Ho is a Principal in the Life Sciences Practice. He is an experienced consultant in legal matters involving intellectual property, antitrust, and other commercial disputes concerning both liability and damages issues.

Dr. Ho has worked on matters involving a range of products, including biologics, small-molecule drugs, and medical devices. He has built substantial expertise in the business and regulatory considerations underlying drug and medical device development that complement his experience in economic analyses. For nearly a decade, he has been advising clients on disputes regarding efforts in drug development (license disputes and contract breach), antitrust matters (market definition and damages in reverse-payment settlements, and product tying), intellectual property disputes (evaluation of commercial success in ANDA litigation, reasonable royalty, and lost profit analyses), pricing (price fixing and welfare analyses), and product labeling matters (including both consumer and pharmaceutical product claims).

Dr. Ho’s doctoral work focused on industrial organization and the economic and strategic evaluation of firm behavior and contracting. His work has been published in the American Economic Review and the Journal of Industrial Economics.

Selected Engagements

  • 01
    CRA consultants calculate damages in a false advertising matter under the Lanham Act
    CRA was retained by counsel for the plaintiff, a manufacturer of medical apparel, to determine damages relating to a false advertising matter under the Lanham...
    View engagement
  • 02
    Evaluation of a blockbuster heart failure medication
    On behalf of a plaintiff for a blockbuster heart failure fixed-dose combination medication, CRA was retained to assess the commercial success of the product...
    View engagement
  • 03
    AAA dispute involving the scope and breadth of exclusivity of a development deal for monoclonal antibodies
    In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two pharmaceutical companies, CRA...
    View engagement